한글목차

다낭성 난소 증후군(PCOS) 치료 시장은 2025년에 11억 9,520만 달러로 예측되고, 2032년에는 16억 6,610만 달러에 이를 것으로 예상되며, 2025년부터 2032년까지 연평균 복합 성장률(CAGR)은 4.86%를 나타낼 것으로 추정되고 있습니다.

다낭성 난소 증후군(PCOS)은 내분비계 질환의 결과로 난소에 액체로 채워진 작은 가방이 생기는 질병입니다. 임신 고혈압 증후군, 자간전증, 조산을 경험하기 쉽습니다. 또한 PCOS의 여성은 월경 불순, 안드로겐(성 호르몬) 수준의 상승, 과도한 발모, 여드름, 비만을 경험할 수 있습니다.

PCOS의 여성은 심각한 건강 문제를 일으킬 가능성이 높습니다. 이것에는 2형 당뇨병, 고혈압, 심장과 혈관 문제, 자궁암 등이 포함됩니다.

시장 역학

경구 피임약의 효과적인 사용과 제품 가치 증가는 예측 기간 동안 다낭성 난소 증후군(PCOS) 치료 시장을 견인할 수 있습니다. 예를 들어, 2022년 8월 NCBI에 PCOS 치료를 위해 경구 피임약 (OC)의 주요 작용 메커니즘이 월경을 조절하는 것이라는 기사가 발표되었습니다. 또한, 이러한 약물은 테스토스테론 수치를 낮추어 다모증과 여드름을 감소시킵니다.

게다가 다낭성 난소 증후군(PCOS) 치료에 있어서의 새로운 메커니즘에 대한 인식 증가가 예측 기간 중 시장 성장을 뒷받침할 것으로 예상되고 있습니다. 조절인자인 SREBP1의 조절을 통해 IR, 미토콘드리아 기능부전, 산화스트레스를 개선함으로써 쥐의 PCOS 유사 증상이 완화된 것으로 나타났습니다.

본 연구의 주요 특징

• 본 보고서는 세계의 다낭성 난소 증후군(PCOS) 치료 시장을 상세하게 분석하여 2024년을 기준연도로 한 예측기간 2025-2032년 시장 규모 및 연간 평균 성장률(CAGR%)을 제공합니다.
• 다양한 부문에 걸친 잠재적인 수익 기회를 해명해, 이 시장의 매력적인 투자 제안의 매트릭스에 대해서 해설했습니다.
• 또한 시장 성장 촉진요인, 억제요인, 기회, 신제품의 출시나 승인, 시장 동향, 지역별 전망, 주요 기업이 채용하는 경쟁 전략 등에 관한 중요한 인사이트도 제공합니다.
• 세계의 다낭성 난소 증후군(PCOS) 치료 시장에 있어서 주요 기업 프로파일을, 기업 하이라이트, 제품 포트폴리오, 주요 하이라이트, 업적, 전략 등의 파라미터에 근거해 제공합니다.
• 세계의 다낭성 난소 증후군(PCOS) 치료 시장 보고서는 투자자, 공급업체, 제품 제조업체, 유통업체, 신규 참가자, 재무 분석가 등 이 업계의 다양한 이해관계자에 대응하고 있습니다.
• 이해관계자는 세계의 다낭성 난소 증후군(PCOS) 치료 시장 분석에 사용되는 다양한 전략 매트릭스를 통해 의사 결정을 용이하게 할 수 있습니다.

목차

제1장 조사의 목적과 전제조건

• 조사 목적
• 전제조건
• 약어

제2장 시장 전망

• 보고서 설명
  • 시장 정의와 범위
• 주요 요약
• Coherent Opportunity Map(COM)

제3장 시장 역학, 규제, 동향 분석

• 시장 역학
  • 성장 촉진요인
  • 성장 억제요인
  • 시장 매력 분석
  • 시장 기회
• 역학
• 규제 시나리오
• 제품 발매
• 합병, 인수, 제휴
• 주요 발전
• 시장 동향
• PEST 분석
• Porter's Five Forces 분석
• 위험과 부작용
• 주요 시장 기업에 의한 신규 투자
• 파이프라인 분석
• 공급망 분석
• 가격 분석
• 브랜드 분석

제4장 세계의 다낭성 난소 증후군(PCOS) 치료 시장 - 코로나 바이러스(COVID-19) 팬데믹의 영향

• 경제에 미치는 영향
• COVID-19 역학
• 임상시험에 대한 영향

제5장 세계의 다낭성 난소 증후군(PCOS) 치료 시장, 약제 클래스별(2020-2032년)

• 경구 피임약
• 인슐린 저항성 개선제
• 항우울제
• 오르니틴 탈탄산효소 억제제
• 아로마타제 억제제 및 SERM
• 이뇨제

제6장 세계의 다낭성 난소 증후군(PCOS) 치료 시장, 유통 채널별(2020-2032년)

• 병원 약국
• 소매 약국
• 온라인 약국

제7장 세계의 다낭성 난소 증후군(PCOS) 치료 시장, 지역별(2020-2032년)

• 북미
  • 미국
  • 캐나다
• 라틴아메리카
  • 브라질
  • 멕시코
  • 아르헨티나
  • 기타 라틴아메리카
• 유럽
  • 영국
  • 독일
  • 이탈리아
  • 프랑스
  • 스페인
  • 러시아
  • 기타 유럽
• 아시아태평양
  • 중국
  • 인도
  • 일본
  • ASEAN
  • 호주
  • 한국
  • 기타 아시아태평양
• 중동
  • GCC
  • 이스라엘
  • 기타 중동
• 아프리카
  • 북아프리카
  • 중앙 아프리카
  • 남아프리카

제8장 경쟁 구도

• Sanofi SA
• Amneal Pharmaceuticals, Inc.
• Laurus Labs Limited
• Zydus Pharmaceuticals, Inc.
• Prasco Laboratories
• Reddy's Laboratories
• Cadila Pharmaceuticals
• Novartis International AG
• Concordia Pharmaceuticals Inc.
• Covis Pharmaceuticals, Inc.
• Cardinal Health
• Aphena Pharma Solutions Tennessee, Inc.
• Mylan NV
• McKesson Corporation
• Teva Pharmaceutical Industries Ltd
• Lupin Pharmaceutical
• Sun Pharmaceutical Industries Ltd.

제9장 섹션

• 조사방법
• 출판사에 대해

영문목차

Polycystic Ovary Syndrome (PCOS) Treatment Market is expected to be USD 1,195.2 Mn in 2025 and is anticipated to reach USD 1,666.1 Mn in 2032 at a compound annual growth rate (CAGR) of 4.86% for the forecast period of 2025 to 2032

Polycystic Ovarian Syndrome (PCOS) can be described as small sacs filled with fluid develop on the ovaries as a result of the endocrine system condition. Women with PCOS who are of childbearing age are affected. PCOS-positive women are more likely to experience miscarriage, gestational diabetes, pregnancy-induced hypertension, preeclampsia, and early birth. Moreover, women with PCOS may experience irregular menstrual cycles, elevated androgen (sex hormone) levels, excessive hair growth, acne, and obesity.

Women who have PCOS are more likely to develop serious health issues. These include type 2 diabetes, high blood pressure, heart and blood vessel problems, and uterine cancer. Women suffering from PCOS frequently struggle to conceive (fertility).

Market Dynamics

Effective use of oral contraceptives and increasing product value can drive the polycystic ovary syndrome (PCOS) treatment market over the forecast period. For instance, in August 2022, an article was published in the NCBI, according to which, for the treatment of PCOS, the major mechanism of action of oral contraceptives (OCs) is to control menstruation. These drugs also reduce hirsutism and acne by lowering testosterone levels. Thus, oral contraceptives are primary treatment for the polycystic ovary syndrome.

Moreover, rising awareness about novel mechanisms in the treatment of Polycystic Ovary Syndrome (PCOS) is anticipated to boost the growth of the market over the forecast period. For instance, according to research study published by Department of Obstetrics and Gynecology, China in November 2020, stated that the electroacupuncture (EA) intervention alleviated PCOS-like symptoms in rats by improving IR, mitochondrial dysfunction and oxidative stress through regulation of SREBP1, a regulator of lipid metabolism. The study findings illuminate the novel protective mechanisms of EA in the treatment of PCOS.

Key features of the study:

• This report provides in-depth analysis of the global Polycystic Ovary Syndrome (PCOS) Treatment market, and provides market size (US$ Million) and Compound Annual Growth Rate (CAGR%) for the forecast period 2025-2032, considering 2024 as the base year
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
• It profiles key players in the Global Polycystic Ovary Syndrome (PCOS) Treatment Market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
• Key companies covered as a part of this study Key companies covered as a part of this study Sanofi S.A., Amneal Pharmaceuticals, Inc., Laurus Labs Limited, Zydus Pharmaceuticals, Inc., Prasco Laboratories, Dr. Reddy's Laboratories, Cadila Pharmaceuticals, Novartis International AG, Concordia Pharmaceuticals Inc., Evotec SE, Covis Pharmaceuticals, Inc., Cardinal Health, Aphena Pharma Solutions Tennessee, Inc., Mylan N.V., McKesson Corporation, Teva Pharmaceutical Industries Ltd, Lupin Pharmaceutical and Sun Pharmaceutical Industries Ltd., Bayer AG, and other prominent players Insights from this report will allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• The global Polycystic Ovary Syndrome (PCOS) Treatment Market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global Polycystic Ovary Syndrome (PCOS) Treatment Market

Market Segmentation

• By Drug Class
  • Oral contraceptives
  • Insulin Sensitizing Agents
  • Anti-Depressants
  • Ornithine Decarboxylase Inhibitors
  • Aromatase Inhibitors & SERMs
  • Diuretics
• By Distribution Channel
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
• By Region
  • North America
  • U.S.
  • Canada
  • Latin America
  • Brazil
  • Argentina
  • Mexico
  • Rest of Latin America
  • Europe
  • Germany
  • U.K.
  • Spain
  • France
  • Italy
  • Russia
  • Rest of Europe
  • Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
  • ASEAN
  • Rest of Asia Pacific
  • Middle East
  • GCC Countries
  • Israel
  • Rest of Middle East
  • Africa
  • South Africa
  • North Africa
  • Central Africa
• Company Profiles
  • Sanofi S.A.
  • Amneal Pharmaceuticals, Inc.
  • Laurus Labs Limited
  • Zydus Pharmaceuticals, Inc.
  • Prasco Laboratories
  • Reddy's Laboratories
  • Cadila Pharmaceuticals
  • Novartis International AG
  • Concordia Pharmaceuticals Inc.
  • Covis Pharmaceuticals, Inc.
  • Cardinal Health
  • Aphena Pharma Solutions Tennessee, Inc.
  • Mylan N.V.
  • McKesson Corporation
  • Teva Pharmaceutical Industries Ltd
  • Lupin Pharmaceutical
  • Sun Pharmaceutical Industries Ltd.

Table of Contents

1. Research Objectives and Assumptions

• Research Objectives
• Assumptions
• Abbreviations

2. Market Purview

• Report Description
  • Market Definition and Scope
• Executive Summary
  • Market Snapshot, By Drug Class
  • Market Snapshot, By Distribution Channel
  • Market Snapshot, By Region
• Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

• Market Dynamics
  • Drivers
  • Restraints
  • Market Attractiveness Analysis
  • Market Opportunities
• Epidemiology
• Regulatory Scenario
• Product Launches
• Merger, Acquisition, Collaborations
• Key Developments
• Market Trends
• PEST Analysis
• PORTER'S Analysis
• Risk and Adverse Effects
• New Investments by Major Market Players
• Pipeline Analysis
• Supply Chain Analysis
• Pricing Analysis
• Brand Analysis

4. Global Polycystic Ovary Syndrome (PCOS) Treatment Market - Impact of Coronavirus (Covid-19) Pandemic

• Economic Impact
• COVID-19 Epidemiology
• Impact on Clinical Trials

5. Global Polycystic Ovary Syndrome (PCOS) Treatment Market, By Drug Class, 2020 - 2032, (US$ Million)

• Introduction
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021 - 2032
  • Segment Trends
• Oral contraceptives
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Million)
• Insulin Sensitizing Agents
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Million)
• Anti- Depressants
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Million)
• Ornithine Decarboxylase Inhibitors
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Million)
• Aromatase Inhibitors & SERMs
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Million)
• Diuretics
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Million)

6. Global Polycystic Ovary Syndrome (PCOS) Treatment Market, By Distribution Channel, 2020 - 2032, (US$ Million)

• Introduction
  • Market Share Analysis, 2025 and 2032(%)
  • Y-o-Y Growth Analysis, 2021 - 2032
  • Segments Trends
• Hospital Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Million)
• Retail Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Million)
• Online Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Million)

7. Global Polycystic Ovary Syndrome (PCOS) Treatment Market, By Region, 2020 - 2032, (US$ Million)

• Introduction
  • Market Share Analysis, By Region, 2025 and 2032(%)
  • Y-o-Y Growth Analysis, For Regions, 2021-2032
  • Regional Trends
• North America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020 - 2032, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2032, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (US$ Million)
    • U.S.
    • Canada
• Latin America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020 - 2032, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2032, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (US$ Million)
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
• Europe
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020 - 2032, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2032, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (US$ Million)
    • U.K.
    • Germany
    • Italy
    • France
    • Spain
    • Russia
    • Rest of Europe
• Asia Pacific
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020 - 2032, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2032, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (US$ Million)
    • China
    • India
    • Japan
    • ASEAN
    • Australia
    • South Korea
    • Rest of Asia Pacific
• Middle East
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020 - 2032, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2032, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (US$ Million)
    • GCC
    • Israel
    • Rest of Middle East
• Africa
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020 - 2032, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2032, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2020 - 2032, (US$ Million)
    • North Africa
    • Central Africa
    • South Africa

8. Competitive Landscape

• Sanofi S.A.
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Amneal Pharmaceuticals, Inc.
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Laurus Labs Limited
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Zydus Pharmaceuticals, Inc.
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Prasco Laboratories
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Reddy's Laboratories
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Cadila Pharmaceuticals
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Novartis International AG
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Concordia Pharmaceuticals Inc.
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Covis Pharmaceuticals, Inc.
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Cardinal Health
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Aphena Pharma Solutions Tennessee, Inc.
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Mylan N.V.
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• McKesson Corporation
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Teva Pharmaceutical Industries Ltd
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Lupin Pharmaceutical
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Sun Pharmaceutical Industries Ltd.
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies

9. Section

• Research Methodology
• About Us